BioCentury | Apr 23, 2020
Product Development

Roche reveals trial failures

...pediatric study is ongoing. The Phase III MIRROS trial of MDM2 antagonist idasanutlin (RG7388) plus cytarabine...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...approval from FDA in combination with azacitidine, decitabine or low-dose cytarabine to treat AML; a Venclexta/cytarabine...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

...myelogenous leukemia. The BCL-2 inhibitor plus low-dose cytarabine failed to improve overall survival compared with cytarabine...
BioCentury | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

...from Beta Pharma (Princeton, N.J.); as well as floxuridine, cyclophosphamide, tegafur, ifosfamide, fludarabine, gemcitabine and cytarabine...
BioCentury | Jun 4, 2019
Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

...pediatric AML, gemcitabine increased survival and decreased tumor burden in the peripheral blood compared with cytarabine...
...include testing the three drugs in combination with other chemotherapies in the models. The generic cytarabine...
BioCentury | Nov 30, 2018
Clinical News

FDA approves two drugs for first-line AML

...candidate. FDA approved Daurismo glasdegib from Pfizer Inc. (NYSE:PFE) for use in combination with low-dose cytarabine...
...Venclexta venetoclax from AbbVie Inc. (NYSE:ABBV) and Genentech Inc. for use in combination with low-dose cytarabine...
...based on data from the Phase II BRIGHT 1003 trial, in which Daurismo plus low-dose cytarabine...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...associated with improved OS in AML patients treated with the hedgehog antagonist glasdegib plus low-dose cytarabine...
BioCentury | Nov 21, 2018
Company News

FDA approves two drugs for first-line AML

...candidate. FDA approved Daurismo glasdegib from Pfizer Inc. (NYSE:PFE) for use in combination with low-dose cytarabine...
...Venclexta venetoclax from AbbVie Inc. (NYSE:ABBV) and Genentech Inc. for use in combination with low-dose cytarabine...
...based on data from the Phase II BRIGHT 1003 trial, in which Daurismo plus low-dose cytarabine...
BioCentury | Nov 9, 2018
Company News

NICE recommends Jazz's Vyxeos for AML

...The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with...
...leukemia (AML) or AML with myelodysplasia-related changes. Vyxeos is a liposomal formulation of daunorubicin and cytarabine...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...million in last year’s quarter but shy of the Street’s expectation of $482.7 million. Vyxeos daunorubicin/cytarabine...
Items per page:
1 - 10 of 477